Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients

Risk stratification of multiple myeloma (MM) at diagnosis is critical. We examined the ability of hematopoietic indices including mean corpuscular volume (MCV), hemoglobin (Hgb), and platelet (Plt) to predict outcomes. This was a retrospective study of patients treated at Mayo Clinic between January 2004 and April 2018. We incorporated three variables (Hgb < 10 g/dL, Plt < 150 × 10⁹/L, and MCV > 96 fL), assigning a score of 1 to each. We identified 1540 newly diagnosed MM patients, of whom 707 (46%) had a score of 0, 513 (33%) had a score of 1, 260 (17%) had a score of 2, and 60 (4%) had a score of 3. The score risk stratified patients into four groups with differing survivals. The median PFS was 32.3 months for score 0, 24.8 months for score 1, 21.7 months for score 2, and 18.3 months for score 3, for P <.001. The median OS was 80.7 months for score 0, 59.9 months for score 1, 51.7 months for score 2, and 31.3 months for score 3, P <.0001. Predictors of OS on the multivariable analysis were age ≥ 65 (HR, 1.93; P <.0001), R-ISS stage (1-2 vs 3) (HR, 0.48; P <.0001), and hematopoietic score (0-2 vs 3) (HR, 0.51; P =.006). A hematopoietic score can predict survival in newly diagnosed myeloma patients.